Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mingjiang Xu

Showing results (31-40 of 139) with videos related to

Pageof 14
Sort By:
Toxicology and Applied Pharmacology|November 10, 2020
A novel salviadione derivative, compound 15a, attenuates diabetes-induced renal injury by inhibiting NF-κB-mediated inflammatory responsesLi Li, Chunyong Ding, Chunpeng Zou, et al.
British Journal of Haematology|April 6, 2007
Haematopoietic cell lineage distribution of MPLW515L/K mutations in patients with idiopathic myelofibrosisWen-Yang Hu, Yan Zhao, Takefumi Ishii, et al.
Experimental Hematology|October 24, 2023
MiR-223-3p promotes genomic stability of hematopoietic progenitors after radiationShi Chen, Gayathri Srinivasan, Aruna Jaiswal, et al.
Blood|August 2, 2011
Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignanciesZhe Li, Xiaoqiang Cai, Chen-Leng Cai, et al.
Blood Cells, Molecules & Diseases|September 19, 2009
Human CD34+ cells are capable of generating normal and JAK2V617F positive endothelial like cells in vivoSelcuk Sozer, Takefumi Ishii, Maria Isabel Fiel, et al.
Blood Cells, Molecules & Diseases|August 22, 2008
Circulating angiogenic monocyte progenitor cells are reduced in JAK2V617F high allele burden myeloproliferative disordersSelcuk Sozer, Xiaoli Wang, Wei Zhang, et al.
Clinical Pharmacology and Therapeutics|January 25, 2021
Use of Partial Area Under the Curve in Bioavailability or Bioequivalence Assessments: A Regulatory PerspectiveLanyan Fang, Ramana Uppoor, Mingjiang Xu, et al.
Clinical Pharmacology and Therapeutics|September 17, 2020
Applications of Adaptive Designs in Generic Drug DevelopmentJieon Lee, Kairui Feng, Mingjiang Xu, et al.
Cell & Bioscience|June 12, 2015
Biologically active, high levels of interleukin-22 inhibit hepatic gluconeogenesis but do not affect obesity and its metabolic consequencesOgyi Park, Sung Hwan Ki, Mingjiang Xu, et al.
Cancer Research|July 10, 2007
Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosisJun Shi, Yan Zhao, Takefumi Ishii, et al.
Pageof 14

Showing results (31-40 of 139) with videos related to

Sort By:
Pageof 14
Toxicology and Applied Pharmacology|November 10, 2020
A novel salviadione derivative, compound 15a, attenuates diabetes-induced renal injury by inhibiting NF-κB-mediated inflammatory responsesLi Li, Chunyong Ding, Chunpeng Zou, et al.
British Journal of Haematology|April 6, 2007
Haematopoietic cell lineage distribution of MPLW515L/K mutations in patients with idiopathic myelofibrosisWen-Yang Hu, Yan Zhao, Takefumi Ishii, et al.
Experimental Hematology|October 24, 2023
MiR-223-3p promotes genomic stability of hematopoietic progenitors after radiationShi Chen, Gayathri Srinivasan, Aruna Jaiswal, et al.
Blood|August 2, 2011
Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignanciesZhe Li, Xiaoqiang Cai, Chen-Leng Cai, et al.
Blood Cells, Molecules & Diseases|September 19, 2009
Human CD34+ cells are capable of generating normal and JAK2V617F positive endothelial like cells in vivoSelcuk Sozer, Takefumi Ishii, Maria Isabel Fiel, et al.
Blood Cells, Molecules & Diseases|August 22, 2008
Circulating angiogenic monocyte progenitor cells are reduced in JAK2V617F high allele burden myeloproliferative disordersSelcuk Sozer, Xiaoli Wang, Wei Zhang, et al.
Clinical Pharmacology and Therapeutics|January 25, 2021
Use of Partial Area Under the Curve in Bioavailability or Bioequivalence Assessments: A Regulatory PerspectiveLanyan Fang, Ramana Uppoor, Mingjiang Xu, et al.
Clinical Pharmacology and Therapeutics|September 17, 2020
Applications of Adaptive Designs in Generic Drug DevelopmentJieon Lee, Kairui Feng, Mingjiang Xu, et al.
Cell & Bioscience|June 12, 2015
Biologically active, high levels of interleukin-22 inhibit hepatic gluconeogenesis but do not affect obesity and its metabolic consequencesOgyi Park, Sung Hwan Ki, Mingjiang Xu, et al.
Cancer Research|July 10, 2007
Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosisJun Shi, Yan Zhao, Takefumi Ishii, et al.
Pageof 14